Evidence map›Paper›PMID 41877180›Full record

ArticleChinese medicine2026

Gut microbiota-metabolism-immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment.

Xuemei Zhang, Liming Zheng, Jia Shi, Shihan Yu, Wenlan Zheng, Hao Liu, Zhengzheng Wu, Hai Feng, Yueqiu Gao, Zhuo Yu

Abstract read
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuemei Zhang *Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Liming Zheng *Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Jia ShiDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Shihan YuDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Wenlan ZhengDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Hao LiuDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Zhengzheng WuDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China.
Hai FengInstitute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. fogsea@163.com.
Yueqiu GaoDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China. gaoyueqiu@shutcm.edu.cn.
Zhuo YuDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, China. zhuoyu@shutcm.edu.cn.

Funding

National Natural Science Foundation of China 82074154
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy characterized by complex metabolic dysregulation and immune evasion mechanisms, leading to poor prognosis and limited treatment efficacy. Growing evidence underscores the critical involvement of gut microbiota dysbiosis in HCC pathogenesis, wherein microbial communities and their bioactive metabolites dynamically influence the hepatic immune microenvironment and drive tumorigenesis. Emerging evidence indicates that Traditional Chinese Medicine (TCM) exerts therapeutic effects against HCC by modulating the gut-liver axis through multiple mechanisms, including remodeling gut microbial composition, regulating microbiota-derived metabolites, and fine-tuning hepatic immune responses, thus establishing a novel effective paradigm for HCC therapy. This article comprehensively reviews the intricate interactions between TCM and the gut microbiota-metabolism-immunity axis, elucidating the pivotal roles of gut microbiota and their metabolites in HCC pathogenesis and progression. Furthermore, we systematically summarize recent advances in understanding how TCM exerts anti-HCC effects through microbiota-mediated immunomodulation, with a particular focus on regulatory mechanisms involving microbial metabolites and hepatic immune responses. These findings provide valuable insights and establish a conceptual framework for future research in this burgeoning field.

Indexed as

Gut microbiotaHepatocellular carcinomaImmunityMicrobial metabolitesTraditional Chinese Medicine

Identifiers

PMID41877180
PMCPMC13011729

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.